“Given the experience of conducting such studies, the successful results of preclinical and clinical studies, the FMBA of Russia is considering the possibility of a clinical trial of the Convasel vaccine in people over 60 years of age in 2022,” she told TASS.
Earlier, the FMBA announced the launch of industrial production of the Convasel vaccine.
Post-registration trials are planned for the end of summer 2022.